Cardiología y enfermedades cardiovasculares. Varios autores

Чтение книги онлайн.

СКАЧАТЬ with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2016;37(27):2129-2200.

4. Borlaug BA, Redfield MM. Diastolic and systolic heart failure are distinct phenotypes within the heart failure spectrum. Circulation. 2011;123(18):2006-2014. https://doi.org/10.1161/CIRCULATIONAHA.110.954388

5. Redfield MM. Heart failure with preserved ejection fraction. N Engl J Med. 2016;375(19):1868-1877. DOI: 10.1056/NEJMcp1511175

6. Steinberg BA, Zhao X, Heidenreich PA, et al. Trends in patients hospitalized with heart failure and preserved left ventricular ejection fraction: prevalence, therapies, and outcomes. Circulation. 2012;126(1):65-75. https://doi.org/10.1161/CIRCULATIONAHA.111.080770

7. Borlaug BA, Paulus WJ. Heart failure with preserved ejection fraction: pathophysiology, diagnosis, and treatment. Eur Heart J. 2011;32(6):670-679. https://doi.org/10.1093/eurheartj/ehq426

8. Ho JE, Enserro D, Brouwers FP, et al. Predicting heart failure with preserved and reduced ejection fraction: the international collaboration on heart failure subtypes. Circ Heart Fail. 2016;9(6):e003116. https://doi.org/10.1161/CIRCHEARTFAILURE.115.003116Cir

9. Parikh KS, Sharma K, Fiuzat M, et al. Heart failure with preserved ejection fraction expert panel report: current controversies and implications for clinical trials. JACC Heart Fail. 2018;6(8):619-632. DOI: 10.1016/j.jchf.2018.06.008

10. Gerber Y, Weston SA, Redfield MM, et al. A contemporary appraisal of the heart failure epidemic in Olmsted County, Minnesota, 2000 to 2010. JAMA Intern Med. 2015;175(6):996-1004. doi:10.1001/jamainternmed.2015.0924

11. Dunlay SM, Roger VL, Redfield MM. Epidemiology of heart failure with preserved ejection fraction. Nat Rev Cardiol. 2017;14:591-602. https://doi.org/10.1038/nrcardio.2017.65

12. Ceia F, Fonseca C, Mota T, et al. Prevalence of chronic heart failure in Southwestern Europe: the EPICA study. Eur J Heart Fail. 2002;4(4):531-539. https://doi.org/10.1016/S1388-9842(02)00034-X

13. Mohammed SF, Borlaug BA, Roger VL, et al. Comorbidity and ventricular and vascular structure and function in heart failure with preserved ejection fraction: a community-based study. Circ Heart Fail. 2012;5(6):710-719. https://doi.org/10.1161/CIRCHEARTFAILURE.112.968594

14. Gladden JD, Linke WA, Redfield MM. Heart failure with preserved ejection fraction. Pflug Arch Eur J Phy. 2014;466:1037-1053. https://doi.org/10.1007/s00424-014-1480-8

15. Loai S, Cheng HLM. Heart failure with preserved ejection fraction: the missing pieces in diagnostic imaging. Heart Fail Rev. 2020;25:305-319. https://doi.org/10.1007/s10741-019-09836-8

16. Lim SL, Lam CS, Segers VF, et al. Cardiac endothelium-myocyte interaction: clinical opportunities for new heart failure therapies regardless of ejection fraction. Eur Heart J. 2015;36(31):2050-2060. https://doi.org/10.1093/eurheartj/ehv132

17. Van Heerebeek L, Hamdani N, Falcao-Pires I, et al. Low myocardial protein kinase G activity in heart failure with preserved ejection fraction. Circulation. 2012;126(7):830-839. https://doi.org/10.1161/CIRCULATIONAHA.111.076075

18. Borlaug BA, Olson TP, Lam CS, et al. Global cardiovascular reserve dysfunction in heart failure with preserved ejection fraction. J Am Coll Cardiol. 2010;56(11):845-854. DOI: 10.1016/j.jacc.2010.03.077

19. Paulus WJ, Tschöpe C. A novel paradigm for heart failure with preserved ejection fraction: comorbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial inflammation. J Am Coll Cardiol. 2013;62(4):263-271. DOI: 10.1016/j.jacc.2013.02.092

20. Westermann D, Lindner D, Kasner M, et al. Cardiac inflammation contributes to changes in the extracellular matrix in patients with heart failure and normal ejection fraction. Circ Heart Fail. 2011;4(1):44-52. https://doi.org/10.1161/CIRCHEARTFAILURE.109.931451C

21. Campbell RT, McMurray JJ. Comorbidities and differential diagnosis in heart failure with preserved ejection fraction. Heart Fail Clin. 2014;10(3):481-501. https://doi.org/10.1016/j.hfc.2014.04.009

22. Hippisley-Cox J, Coupland C. Diabetes treatments and risk of heart failure, cardiovascular disease, and all cause mortality: cohort study in primary care. BMJ. 2016; 354:i3477. https://doi.org/10.1136/bmj.i3477

23. Tsujimoto T, Kajio H. Abdominal obesity is associated with an increased risk of all-cause mortality in patients with HFpEF. J Am Coll Cardiol. 2017;70(22):2739-2749. DOI: 10.1016/j.jacc.2017.09.1111

24. Pieske B, Tschöpe C, De Boer RA, et al. How to diagnose heart failure with preserved ejection fraction: the HFA-PEFF diagnostic algorithm: a consensus recommendation from the Heart Failure Association (HFA) of the European Society of Cardiology (ESC). Eur Heart J. 2019;40(40):3297-3317. https://doi.org/10.1093/eurheartj/ehz641

25. Silverman DN, Shah SJ. Treatment of heart failure with preserved ejection fraction (HFpEF): The phenotype-guided approach. Curr Treat Options Cardiovasc Med. 2019;21:20. https://doi.org/10.1007/s11936-019-0709-4

26. Pitt B, Pfeffer MA, Assmann SF, et al. Spironolactone for heart failure with preserved ejection fraction. N Engl J Med. 2014;370:1383-1392. DOI: 10.1056/NEJMoa1313731

27. Shah AM, Shah SJ, Anand IS, et al. Cardiac structure and function in heart failure with preserved ejection fraction: baseline findings from the echocardiographic study of the Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist trial. Circ Heart Fail. 2014;7(1): 104-115. https://doi.org/10.1161/CIRCHEARTFAILURE.113.000887

28. Pfeffer MA, Claggett B, Assmann SF, et al. Regional variation in patients and outcomes in the treatment of preserved cardiac function heart failure with an aldosterone antagonist (TOPCAT) trial. Circulation. 2015;131(1):34-42. https://doi.org/10.1161/CIRCULATIONAHA.114.013255

29. De Denus S, O’Meara E, Desai AS, et al. Spironolactone metabolites in TOPCAT: new insights into regional variation. N Engl J Med. 2017;376(17): 1690-1692. doi: 10.1056/NEJMc1612601

30. Solomon SD, Zile M, Pieske B, et al. The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trial. The Lancet. 2012;380(9851):1387-1395. https://doi.org/10.1016/S0140-6736(12)61227-6

31. Solomon SD, McMurray JJ, Anand IS, et al. Angiotensin: neprilysin inhibition in heart failure with preserved ejection fraction. N Engl J Med. 2019;381(17): 1609-1620. DOI: 10.1056/NEJMoa1908655

СКАЧАТЬ